Bayer names new chairman

25 February 2016

German pharma major Bayer (BAYN: DE) has announced that Werner Baumann is to take over as chairman of the firm's board of management on May 1.

The 53-year-old replaces current chairman and chief executive Marijn Dekkers who is standing down eight months before his contract was due to end. Dr Dekkers said he had proposed dissolving his contract early to Bayer’s supervisory board.

“With its clear focus on the life science businesses and its new organizational structure, Bayer is in a position of strength,” said Dr Dekkers. The course for successful future development has already been set at all levels. Also with a successor from within the company there will be no need for a familiarization period.I would like to wish Werner Baumann every success in his new role.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK